Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-22
2010-06-08
Canella, Karen A (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007230, C530S350000
Reexamination Certificate
active
07732148
ABSTRACT:
A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.
REFERENCES:
patent: 2002/0110832 (2002-08-01), Pyle et al.
patent: 2002/0168696 (2002-11-01), Hanash et al.
patent: 2003/0108963 (2003-06-01), Schlegel et al.
patent: 2003/0152923 (2003-08-01), Yakhini et al.
patent: 2003/0165954 (2003-09-01), Katagiri et al.
patent: 2003/0175736 (2003-09-01), Chinnaiyan et al.
patent: 2003/0232399 (2003-12-01), Robertson et al.
patent: 2004/0033502 (2004-02-01), Williams et al.
patent: 2004/0096916 (2004-05-01), Kellner et al.
patent: 2004/0241653 (2004-12-01), Feinstein et al.
patent: WO 2004/079368 (2004-09-01), None
patent: WO 2005/078124 (2005-08-01), None
Stites et al (Medical Immunology, 9th Ed, Appleton and Lange, Stamford, 1997, p. 250-251).
Taber's Cyclopedic Medical Dictionary (1985, F.A. Davis Company, Philadelphia, p. 274).
Busken, C et al, (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Kaiser (Science, 2006, 313: 1370).
Jiang et al (JBC, 2003, 278(7) 4763-4769).
Matsushita et al (FEBS Letters, 1999, vol. 443, pp. 348-352).
Singh et al (Glycobiology, 2001, vol. 11, pp. 587-592).
Le Cabec et al. (Biochemical J. 1994 303:481-487).
Markku H. Vaarala et al., “Differentially Expressed Genes in Two LNCaP Prostate Cancer Cell Lines Reflecting Changes during Prostate Cancer Progression,” Laboratory Investigation, vol. 80, No. 8, Aug. 2000, pp. 1259-1268.
Ayodele A. Alaiya et al., “Protein expression profiling in human lung, breast, bladder, renal, colorectal and ovarian cancers,” Journal of Chromatography B: Biomedical Sciences & Applications, vol. 787, No. 1, Apr. 5, 2003, pp. 207-222.
Seung-won Lee et al., “Revealing urologic diseases by proteomic techniques,” Journal of Chromatography B: Biomedical Sciences & Applications, vol. 815, No. 1-2, Feb. 5, 2005, pp. 203-213.
Saverio Cinieri et al., “Innovation in care and research: Meeting highlights from the Seventh Milan Breast Cancer Conference (Milan, Jun. 15-17, 2005),” The Breast, vol. 15, No. 2, Apr. 2006, pp. 232-245.
Carter et al., “Improved Biomarkers for Prostate Cancer: A Definite Need,” Journal of the National Cancer Institute, Jun. 2, 2004, vol. 96, No. 11, pp. 813-815.
Antenor et al., “Relationship between Initial Prostate Specific Antigen Level and Subsequent Prostate Cancer Detection in a Longitudinal Screening Study,” The Journal of Urology, Jul. 2004, vol. 172, pp. 90-93.
Lilja, Hans, “Biology of Prostate-Specific Antigen,” Urology 62 (Supplement 5A), Nov. 2003, pp. 27-33.
Watson et al., “Future Opportunities for the Diagnosis and Treatment of Prostate Cancer,” Prostate Cancer Prostatic Diseases, 2004, vol. 7, pp. S8-S13.
Demarzo et al., “Pathological and Molecular Aspects of Prostate Cancer,” The Lancet, Mar. 15, 2003, vol. 361, pp. 955-964.
Kumar-Sinha et al., “Molecular Markers to Identify Patients at Risk for Recurrence after Primary Treatment for Prostate Cancer,” Urology 62 (Supplement 6B), Dec. 29, 2003, pp. 19-35.
Moul et al., “Molecular Markers in Prostate Cancer: The Role in Preoperative Staging,” Clinical Prostate Cancer, Jun. 2002, pp. 42-50.
Ahram et al., “Proteomic Analysis of Human Prostate Cancer,” Molecular Carcinogenesis, 2002, vol. 33, pp. 9-15.
Petricoin et al., “Proteomic Approaches in Cancer Risk and Response Assessment,” Trends Molecular Medicine, Feb. 2004, vol. 10, No. 2, pp. 59-64.
Diamandis, E. P., “Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool: Opportunities and Potential Limitations,” Molecular & Cellular Proteomics, 2004, vol. 3, pp. 367-378.
Jacobs et al., “Progress and Challenges in Screening for Early Detection of Ovarian Cancer,” Molecular & Cellular Proteomics, 2004, vol. 3, pp. 355-366.
Lapointe et al., “Gene Expression Profiling Identifies Clinically Relevant Subtypes of Prostate Cancer,” PNAS, Jan. 20, 2004, vol. 101, No. 3, pp. 811-816.
Rossi et al., “Fatty Acid Synthase Expression Defines Distinct Molecular Signatures in Prostate Cancer,” Molecular Cancer Research, Aug. 2003, vol. 1, pp. 707-715.
Parnes et al., “Prostate Cancer Chemoprevention Agent Development: The National Cancer Institute, Division of Cancer Prevention Portfolio,” The Journal of Urology, Feb. 2004, vol. 171, pp. S68-S75.
Eastham, J. A., “Multimodal Treatment Strategies Combining Neoadjuvant Hormonal Therapy and/or Chemotherapy with Radical Prostatectomy in High-Risk Localised Prostate Cancer,” Expert Opinion Investigating Drugs, 2004, vol. 13, pp. 39-46.
Nebert et al., “Pharmacogenomics and ‘Individualized Drug Therapy’: High Expectations and Disappointing Achievements,” Am. J. Pharmacogenomics, 2003, vol. 3, pp. 361-370.
Gerke et al., “Annexins: From Structure to Function,” Physiol. Rev., Apr. 2002. vol. 82, pp. 331-371.
Alaiya et al, “Identification of Proteins in Human Prostate Tumor Material by Two-Dimensional Gel Electrophoresis and Mass Spectrometry,” CMLS Cellular and Molecular Life Sciences, 2001, vol. 58, pp. 307-311.
Niimi et al., “Expression of Annexin A3 in Primary Cultured Parenchymal Rat Hepatocytes and Inhibition of DNA Synthesis by Suppression of Annexin A3 Expression Using RNA Interference,” Biol. Pharm. Bull., 2005, vol. 28, No. 3, pp. 424-428.
Niimi et al., “Specific Expression of Annexin III in Rat-Small-Hepatocytes,” Biochemical and Biophysical Research Communications, 2003, vol. 300, pp. 770-774.
Schartz et al., “From the Antigen-Presenting Cell to the Antigen-Presenting Vesicle: The Exosomes,” Current Opinion in Molecular Therapeutics, 2002, vol. 4, No. 4, pp. 372-381.
Pisitkun et al., “Identification and Proteomic Profiling of Exosomes in Human Urine,” PNAS, Sep. 7, 2004, vol. 101, No. 36, pp. 13368-13373.
Thery et al., “Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles,” Journal of Immunology, 2001, vol. 166, pp. 7309-7318.
Carlsson et al., “Dominant Prostasome Immunogens for Sperm-Agglutinating Autoantibodies of Infertile Men,” Journal of Andrology, Sep./Oct. 2004, vol. 25, No. 5, pp. 699-705.
Oh et al., “Subtractive Proteomic Mapping of the Endothelial Surface in Lung and Solid Tumours for Tissue-Specific Therapy,” Nature, Jun. 10, 2004, vol. 429, pp. 629-635.
Reutelingsperger et al., “Annexin V, the Regulator of Phosphatidylserine-Catalyzed Inflammation and Coagulation during Apoptosis,” CMLS Cellular and Molecular Life Science, 1997, vol. 53, pp. 527-532.
Perretti et al., “Annexin 1 and the Biology of the Neutrophil,” Journal of Leukocyte Biology, Jul. 2004, vol. 75, pp. 25-29.
Maderna et al., “Modulation of Phagocytosis of Apoptotic Neutrophils by Supernatant from Dexamethasone-Treated Macrophages and Annexin-Derived Peptide Ac(2-26),” The Journal of Immunology, 2005, vol. 174, pp. 3727-3733.
Hegmans et al., “Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells,” American Journal of Pathology, May 2004, vol. 164, No. 5, pp. 1807-1815.
Wang et al., “Annexin-Mediated Ca2+ Influx Regulates Growth Plate Chondrocyte Maturation and Apoptosis,” The Journal of Biological Chemistry, Feb. 7, 2003, vol. 278, No. 6, pp. 3762-3769.
Bondanza et al., “Inhibition of Phosphatidylserine Recognition Heightens the Immunogenicity of Irradiated Lymphoma Cells In Vivo,” J. Exp. Med., Nov. 1, 2004, vol. 200, No. 9, pp. 1157-1165.
Kamal et al., “An Annexin 1 (ANXA1)-Derived Peptide Inhibits Prototype Antigen-Driven Human T Cell Th1 and Th2 Responses In Vitro,” Clinical and Experimental Allergy, 2001, vol. 3
Cahill Michael
Schrattenholz Andre
Canella Karen A
DLA Piper (LLP) US
ProteoSys AG
Reddig Peter J
LandOfFree
Annexin A3 for prostate cancer diagnosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Annexin A3 for prostate cancer diagnosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Annexin A3 for prostate cancer diagnosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4245809